Abstract
Background: Puerarin (PR) as one of the main ingredients of the root of the traditional herb Kudzu has been suggested to improve chronic alcohol-induced liver injury. We explore the specific mechanisms of PR on hepatocellular changes after administration of alcohol. Methods: Sprague-Dawley rats were treated with 55% alcohol for 12 weeks to induce a chronic alcoholic liver damage model. Then the rats in each group were administered by oral gavage with zileuton, celecoxib, and PR for 2 weeks, respectively. Results: In the PR group, the weight loss was markedly improved and the abnormal serum alanine aminotransferase and aspartate aminotransferase were significantly lowered after PR treatment when compared to the alcoholic liver injured model group. Pathological examination indicated that alcohol-induced hepatocellular injury was improved by the PR treatment. The 5-lipoxygenase (5-Lox) and cyclooxygenase-2 (Cox-2) at the protein level and the mRNA level were obviously downregulated accompanied with the PR treatment. Meanwhile, the peroxisome proliferator-activated receptor γ (PPAR-γ) at the protein and mRNA level was notably elevated and the tumor necrosis factor α at the protein and mRNA level was markedly decreased following the PR treatment. Conclusion: The possible cytoprotective mechanisms of PR may be involved inhibition of the Cox-2 pathway and the 5-Lox pathway to suppress inflammatory response and regulate the protective factor PPAR-γ expression.
References
1.
Stickel
F
, Datz
C
, Hampe
J
, Bataller
R
. Pathophysiology and management of alcoholic liver disease: update 2016
. Gut Liver
. 2017
Mar
;11
(2
):173
–88
.
[PubMed]
1976-22832.
Williams
R
, Ashton
K
, Aspinall
R
, Bellis
MA
, Bosanquet
J
, Cramp
ME
, et al. Implementation of the lancet standing commission on liver disease in the UK
. Lancet
. 2015
Nov
;386
(10008
):2098
–111
.
[PubMed]
0140-67363.
Mellinger
JL
, Winder
GS
. Alcohol use disorders in alcoholic liver disease
. Clin Liver Dis
. 2019
Feb
;23
(1
):55
–69
.
[PubMed]
1089-32614.
Singh
S
, Osna
NA
, Kharbanda
KK
. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
. World J Gastroenterol
. 2017
Sep
;23
(36
):6549
–70
.
[PubMed]
1007-93275.
Teschke
R
. Alcoholic liver disease: current mechanistic aspects with focus on their clinical relevance
. Biomedicines
. 2019
Sep
;7
(3
):E68
.
[PubMed]
2227-90596.
Jiang
Y
, Zhang
T
, Kusumanchi
P
, Han
S
, Yang
Z
, Liangpunsakul
S
. Alcohol metabolizing enzymes, microsomal ethanol oxidizing system, cytochrome P450 2E1, catalase, and aldehyde dehydrogenase in alcohol-associated liver disease
. Biomedicines
. 2020
Mar
;8
(3
):E63
.
[PubMed]
2227-90597.
Kępka
A
, Zwierz
P
, Chojnowska
S
, Ochocińska
A
, Skorupa
E
, Szczepański
M
, et al. Relation of plasma carnitine and aminotransferases to alcohol dose and time of dependence
. Alcohol
. 2019
Dec
;81
:62
–9
.
[PubMed]
0741-83298.
Martín-Sanz
P
, Mayoral
R
, Casado
M
, Boscá
L
. COX-2 in liver, from regeneration to hepatocarcinogenesis: what we have learned from animal models?
World J Gastroenterol
. 2010
Mar
;16
(12
):1430
–5
.
[PubMed]
1007-93279.
Cheng
Q
, Li
N
, Chen
M
, Zheng
J
, Qian
Z
, Wang
X
, et al. Cyclooxygenase-2 promotes hepatocellular apoptosis by interacting with TNF-α and IL-6 in the pathogenesis of nonalcoholic steatohepatitis in rats
. Dig Dis Sci
. 2013
Oct
;58
(10
):2895
–902
.
[PubMed]
0163-211610.
Brenner
C
, Galluzzi
L
, Kepp
O
, Kroemer
G
. Decoding cell death signals in liver inflammation
. J Hepatol
. 2013
Sep
;59
(3
):583
–94
.
[PubMed]
0168-827811.
Li
L
, Liu
YR
, Gao
S
, Li
JF
, Li
SS
, Zhang
DD
, et al. Inhibition of 5-lipoxygenase pathway attenuates acute liver failure by inhibiting macrophage activation
. J Immunol Res
. 2014
;2014
:697560
.
[PubMed]
2314-715612.
Yousefnia
S
, Momenzadeh
S
, Seyed Forootan
F
, Ghaedi
K
, Nasr Esfahani
MH
. The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity
. Gene
. 2018
Apr
;649
:14
–22
.
[PubMed]
0378-111913.
Zhu
K
, Tang
Y
, Xu
X
, Dang
H
, Tang
LY
, Wang
X
, et al. Non-proteolytic ubiquitin modification of PPARγ by Smurf1 protects the liver from steatosis
. PLoS Biol
. 2018
Dec
;16
(12
):e3000091
.
[PubMed]
1544-917314.
Han
J
, Wang
D
, Li
D
, Chen
X
, Wang
B
, Wang
F
, et al. Licochalcone E protects against carbon tetrachloride‑induced liver toxicity by activating peroxisome proliferator-activated receptor gamma
. Mol Med Rep
. 2017
Oct
;16
(4
):5269
–76
.
[PubMed]
1791-299715.
Planagumà
A
, Clària
J
, Miquel
R
, López-Parra
M
, Titos
E
, Masferrer
JL
, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation
. FASEB J
. 2005
Jul
;19
(9
):1120
–2
.
[PubMed]
0892-663816.
Tsujimoto
S
, Kishina
M
, Koda
M
, Yamamoto
Y
, Tanaka
K
, Harada
Y
, et al. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ
. Int J Mol Med
. 2016
Sep
;38
(3
):721
–8
.
[PubMed]
1107-375617.
Li
R
, Liang
T
, He
Q
, Guo
C
, Xu
L
, Zhang
K
, et al. Puerarin, isolated from Kudzu root (Willd.), attenuates hepatocellular cytotoxicity and regulates the GSK-3β/NF-κB pathway for exerting the hepatoprotection against chronic alcohol-induced liver injury in rats
. Int Immunopharmacol
. 2013
Sep
;17
(1
):71
–8
.
[PubMed]
1567-576918.
Zhao
L
, Wang
Y
, Liu
J
, Wang
K
, Guo
X
, Ji
B
, et al. Protective effects of genistein and puerarin against chronic alcohol-induced liver injury in mice via antioxidant, anti-inflammatory, and anti-apoptotic mechanisms
. J Agric Food Chem
. 2016
Sep
;64
(38
):7291
–7
.
[PubMed]
0021-856119.
Penetar
DM
, Toto
LH
, Farmer
SL
, Lee
DY
, Ma
Z
, Liu
Y
, et al. The isoflavone puerarin reduces alcohol intake in heavy drinkers: a pilot study
. Drug Alcohol Depend
. 2012
Nov
;126
(1-2
):251
–6
.
[PubMed]
0376-871620.
Kołota
A
, Głąbska
D
, Oczkowski
M
, Gromadzka-Ostrowska
J
. Influence of alcohol consumption on body mass gain and liver antioxidant defense in adolescent growing male rats
. Int J Environ Res Public Health
. 2019
Jun
;16
(13
):E2320
.
[PubMed]
1661-782721.
Rossi
RE
, Conte
D
, Massironi
S
. Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: overview of available evidence and open issues
. Dig Liver Dis
. 2015
Oct
;47
(10
):819
–25
.
[PubMed]
1590-865822.
Milat
AM
, Mudnić
I
, Grković
I
, Ključević
N
, Grga
M
, Jerčić
I
, et al. Effects of white wine consumption on weight in rats: do polyphenols matter?
Oxid Med Cell Longev
. 2017
;2017
:8315803
.
[PubMed]
1942-090023.
Ju
Z
, Su
M
, Hong
J
, La Kim
E
, Moon
HR
, Chung
HY
, et al. Design of balanced COX inhibitors based on anti-inflammatory and/or COX-2 inhibitory ascidian metabolites
. Eur J Med Chem
. 2019
Oct
;180
:86
–98
.
[PubMed]
0223-523424.
Echizen
K
, Hirose
O
, Maeda
Y
, Oshima
M
. Inflammation in gastric cancer: interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways
. Cancer Sci
. 2016
Apr
;107
(4
):391
–7
.
[PubMed]
1347-903225.
Martín-Sanz
P
, Casado
M
, Boscá
L
. Cyclooxygenase 2 in liver dysfunction and carcinogenesis: facts and perspectives
. World J Gastroenterol
. 2017
May
;23
(20
):3572
–80
.
[PubMed]
1007-932726.
Chang
YY
, Lin
YL
, Yang
DJ
, Liu
CW
, Hsu
CL
, Tzang
BS
, et al. Hepatoprotection of noni juice against chronic alcohol consumption: lipid homeostasis, antioxidation, alcohol clearance, and anti-inflammation
. J Agric Food Chem
. 2013
Nov
;61
(46
):11016
–24
.
[PubMed]
0021-856127.
Wang
D
, Dubois
RN
. Eicosanoids and cancer
. Nat Rev Cancer
. 2010
Mar
;10
(3
):181
–93
.
[PubMed]
1474-175X28.
Pein
H
, Ville
A
, Pace
S
, Temml
V
, Garscha
U
, Raasch
M
, et al. Endogenous metabolites of vitamin E limit inflammation by targeting 5-lipoxygenase
. Nat Commun
. 2018
Sep
;9
(1
):3834
.
[PubMed]
2041-172329.
Rådmark
O
, Werz
O
, Steinhilber
D
, Samuelsson
B
. 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease
. Biochim Biophys Acta
. 2015
Apr
;1851
(4
):331
–9
.
[PubMed]
0006-300230.
Li
L
, Liu
YR
, Gao
S
, Li
JF
, Li
SS
, Zhang
DD
, et al. Inhibition of 5-lipoxygenase pathway attenuates acute liver failure by inhibiting macrophage activation
. J Immunol Res
. 2014
;2014
:697560
.
[PubMed]
2314-715631.
Pervin
M
, Karim
MR
, Kuramochi
M
, Izawa
T
, Kuwamura
M
, Yamate
J
. Macrophage populations and expression of regulatory inflammatory factors in hepatic macrophage-depleted rat livers under lipopolysaccharide (LPS) treatment
. Toxicol Pathol
. 2018
Jul
;46
(5
):540
–52
.
[PubMed]
0192-623332.
Borges
TK
, Alves
ÉA
, Vasconcelos
HA
, Carneiro
FP
, Nicola
AM
, Magalhães
KG
, et al. Differences in the modulation of reactive species, lipid bodies, cyclooxygenase-2, 5-lipoxygenase and PPAR-γ in cerebral malaria-susceptible and resistant mice
. Immunobiology
. 2017
Apr
;222
(4
):604
–19
.
[PubMed]
0171-298533.
Li
RW
, Lin
GD
, Leach
DN
, Waterman
PG
, Myers
SP
. Inhibition of COXs and 5-LOX and activation of PPARs by Australian Clematis species (Ranunculaceae)
. J Ethnopharmacol
. 2006
Mar
;104
(1-2
):138
–43
.
[PubMed]
0378-874134.
Tsujimoto
S
, Kishina
M
, Koda
M
, Yamamoto
Y
, Tanaka
K
, Harada
Y
, et al. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ
. Int J Mol Med
. 2016
Sep
;38
(3
):721
–8
.
[PubMed]
1107-375635.
Li
RW
, Lin
GD
, Leach
DN
, Waterman
PG
, Myers
SP
. Inhibition of COXs and 5-LOX and activation of PPARs by Australian Clematis species (Ranunculaceae)
. J Ethnopharmacol
. 2006
Mar
;104
(1-2
):138
–43
.
[PubMed]
0378-874136.
Lamas-Paz
A
, Hao
F
, Nelson
LJ
, Vázquez
MT
, Canals
S
, Gómez Del Moral
M
, et al. Alcoholic liver disease: utility of animal models
. World J Gastroenterol
. 2018
Dec
;24
(45
):5063
–75
.
[PubMed]
1007-9327© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
